Stock Track | Ardelyx Surges 5% After Reporting Robust Q3 Revenue Growth and Better-Than-Expected Earnings

Stock Track11-01

Shares of Ardelyx Inc. (ARDX) soared 5.11% on Wednesday, November 1, after the biopharmaceutical company reported strong third-quarter financial results, driven by robust revenue growth and better-than-expected earnings.

The company's total revenue for the quarter ended September 30, 2024, surged 74.2% year-over-year to $98.2 million, exceeding analysts' expectations of $86.64 million. This impressive growth was fueled by increased sales of Ardelyx's two key products, IBSRELA and XPHOZAH.

IBSRELA, a treatment for irritable bowel syndrome with constipation (IBS-C), saw its net product sales nearly double compared to the same period last year, reaching $40.6 million. The sales growth was further bolstered by a 15% increase from the second quarter of 2024, highlighting the product's strong demand and market acceptance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169224834?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-01 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169224834","market":"us","top_or_hot":-1,"title":"Stock Track | Ardelyx Surges 5% After Reporting Robust Q3 Revenue Growth and Better-Than-Expected Earnings","media":"Stock Track","content":"<p>Shares of Ardelyx Inc. (ARDX) soared 5.11% on Wednesday, November 1, after the biopharmaceutical company reported strong third-quarter financial results, driven by robust revenue growth and better-than-expected earnings.</p>\n\n<p>The company's total revenue for the quarter ended September 30, 2024, surged 74.2% year-over-year to $98.2 million, exceeding analysts' expectations of $86.64 million. This impressive growth was fueled by increased sales of Ardelyx's two key products, IBSRELA and XPHOZAH.</p>\n\n<p>IBSRELA, a treatment for irritable bowel syndrome with constipation (IBS-C), saw its net product sales nearly double compared to the same period last year, reaching $40.6 million. The sales growth was further bolstered by a 15% increase from the second quarter of 2024, highlighting the product's strong demand and market acceptance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ardelyx Surges 5% After Reporting Robust Q3 Revenue Growth and Better-Than-Expected Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ardelyx Surges 5% After Reporting Robust Q3 Revenue Growth and Better-Than-Expected Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-01 21:34 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Ardelyx Inc. (ARDX) soared 5.11% on Wednesday, November 1, after the biopharmaceutical company reported strong third-quarter financial results, driven by robust revenue growth and better-...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARDX","symbol_name":"Ardelyx","start_time":0,"source_url":"","article_id":"1169224834","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169224834","pubTimestamp":1730468079,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Ardelyx Inc.  soared 5.11% on Wednesday, November 1, after the biopharmaceutical company reported strong third-quarter financial results, driven by robust revenue growth and better-than-expected earnings.The company's total revenue for the quarter ended September 30, 2024, surged 74.2% year-over-year to $98.2 million, exceeding analysts' expectations of $86.64 million. This impressive growth was fueled by increased sales of Ardelyx's two key products, IBSRELA and XPHOZAH.IBSRELA, a tre","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARDX":"Ardelyx"},"translate_title":"股票追踪Ardelyx在报告第三季度收入强劲增长和好于预期的盈利后飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1},"content_text":"Shares of Ardelyx Inc. (ARDX) soared 5.11% on Wednesday, November 1, after the biopharmaceutical company reported strong third-quarter financial results, driven by robust revenue growth and better-than-expected earnings.\nThe company's total revenue for the quarter ended September 30, 2024, surged 74.2% year-over-year to $98.2 million, exceeding analysts' expectations of $86.64 million. This impressive growth was fueled by increased sales of Ardelyx's two key products, IBSRELA and XPHOZAH.\nIBSRELA, a treatment for irritable bowel syndrome with constipation (IBS-C), saw its net product sales nearly double compared to the same period last year, reaching $40.6 million. The sales growth was further bolstered by a 15% increase from the second quarter of 2024, highlighting the product's strong demand and market acceptance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169224834"}